GENE THERAPY FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

治疗晚期前列腺癌的基因疗法

• 批准号: 6116843
• 负责人: MITCHELL S. STEINER
• 金额: --
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 1999-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116843
• 关键词: antisense nucleic acid; clinical research; gene mutation; gene therapy; human subject; human therapy evaluation; neoplasm /cancer therapy; prostate neoplasms; transfection /expression vector

The focus of this proposal is to utilize novel corrective and cytoablative prostate specific viral based gene therapy to combat advanced prostate cancer. Corrective gene therapy attempts to correct genetic mutations in cancer by either replacing mutated genes with normal ones or suppressing overexpressed stimulatory oncogenes with antisense RNA viral vectors. In contrast, cytoablative gene therapy introduces prodrug enzymes (suicide genes) into cancer cells rendering them capable of activating innocuous agents into cancer-killing chemotherapeutic agents.

该提案的重点是利用新颖的纠正和细节性 前列腺特异性病毒基因疗法以对抗晚期前列腺 癌症。 纠正基因疗法试图纠正基因突变 通过用正常基因代替突变的基因或抑制癌症 具有反义RNA病毒载体的过表达的刺激性致癌基因。 在 对比，细胞掌疗基因疗法引入前药酶（自杀酶 基因）进入癌细胞，使它们能够激活无害 杀死癌症化学治疗剂的药物。